HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma

Peng Liu; Hualin Zhang; Xiaohong Liang; Hongxin Ma; Fang Luan; Bo Wang; Fuxiang Bai; Lifen Gao; Chunhong Ma

doi:10.18632/oncotarget.4804

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma

Peng Liu, Hualin Zhang, Xiaohong Liang, Hongxin Ma, Fang Luan, Bo Wang, Fuxiang Bai, Lifen Gao and Chunhong Ma _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:29048-29059. https://doi.org/10.18632/oncotarget.4804

Metrics: PDF 2866 views | HTML 2741 views | ?

Abstract

Peng Liu1, Hualin Zhang1, Xiaohong Liang1, Hongxin Ma1, Fang Luan2, Bo Wang1, Fuxiang Bai1, Lifen Gao1, Chunhong Ma1

1Key Laboratory for Experimental Teratology of Ministry of Education and Department of Immunology, Shandong University School of Medicine, Jinan, Shandong, 250012, P.R. China

2Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, Shandong, 250021, P.R. China

Correspondence to:

Chunhong Ma, e-mail: [email protected]

Keywords: preS2, miRNA-338-3p, HCC, Hippo pathway, TAZ

Received: January 14, 2015 Accepted: July 24, 2015 Published: August 05, 2015

ABSTRACT

Transactivators encoded by HBV, including HBx and preS2, play critical role in hepatocellular carcinoma (HCC). YAP, a downstream effector of the Hippo pathway, is involved in hepatocarcinogenesis mediated by HBx. Here, we investigated whether preS2, another transactivator encoded by HBV, regulates the Hippo pathway to promote HCC. We found that preS2 overexpression upregulated TAZ, a downstream effector of the Hippo pathway, at protein level but not at mRNA level. preS2 suppressed miRNA-338-3p expression in HCC cell lines. miRNA-338-3p mimics downregulated TAZ, while miRNA-338-3p inhibitor restored the expression of TAZ, suggesting that TAZ is a direct target of miRNA-338-3p. TAZ overexpression stimulated growth of HCC cell lines. Knockdown of TAZ dampened preS2-promoted HCC proliferation and migration. Thus, preS2 upregulates TAZ expression by repressing miRNA-338-3p. TAZ is necessary for preS2-promoted HCC proliferation and migration

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4804

Publication Alerts

Research Papers:

HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma

Abstract